AU Patent

AU2022203481A1 — Polymorphs of sepiapterin and salts thereof

Assigned to PTC Therapeutics MP Inc · Expires 2022-06-16 · 4y expired

What this patent protects

Disclosed herein are solid forms of sepiapterin free base, including an amorphous solid form and polymorphic forms of sepiapterin free base. Further disclosed are crystalline polymorphic forms of sepiapterin salts, particularly sepiapterin hydrochloride salt.

USPTO Abstract

Disclosed herein are solid forms of sepiapterin free base, including an amorphous solid form and polymorphic forms of sepiapterin free base. Further disclosed are crystalline polymorphic forms of sepiapterin salts, particularly sepiapterin hydrochloride salt.

Drugs covered by this patent

Patent Metadata

Patent number
AU2022203481A1
Jurisdiction
AU
Classification
—
Expires
2022-06-16
Drug substance claim
No
Drug product claim
No
Assignee
PTC Therapeutics MP Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.